Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00886535 · ClinicalTrials.gov registry record
Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity
A clinical trial, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- 41
- Enrollment target
NCT00886535 is a clinical trial that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 41 participants.
The verdict
NCT00886535 has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- 41 participants
- Enrollment target
Study Summary
This study will be an open-label prospective observational trial designed to test associations between polymorphisms of candidate genes and tamoxifen. Pre- and post-menopausal women taking tamoxifen as standard therapy or chemopreventive therapy will be included in this study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2010-02 |
| Est. Completion | 2017-07-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00886535
The ClinicalTrials.gov registry entry for NCT00886535 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00886535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00886535 about?
NCT00886535 is a clinical study titled "Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity". This study will be an open-label prospective observational trial designed to test associations between polymorphisms of candidate genes and tamoxifen. Pre- and post-menopausal women taking tamoxifen as standard therapy or chemopreventive therapy will be included in this study.
What is the current status of trial NCT00886535?
This trial is currently completed. The enrollment target is 41 participants. The study started on 2010-02. Estimated completion is 2017-07-27.
Who is sponsoring clinical trial NCT00886535?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.